Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a new investigator-sponsored trial, smaller than previously but with a control arm. Remetinostat was outlicensed to Biossil for up to USD60m in milestones, a limited deal. We update our base case.
LÄS MER
